Your session is about to expire
← Back to Search
Pioglitazone 30 mg for Insulin Resistance
Study Summary
This trial looks at whether giving the drug pioglitazone to men with prostate cancer who are also on ADT will help improve insulin resistance.
- Insulin Resistance
- Prostate Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 3 trial • 936 Patients • NCT01183013Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment open for this particular research effort?
"According to the information on clinicaltrials.gov, this research is searching for participants and has been available since December 1st 2021 with edits having taken place as recently as June 30th 2022."
Is the age cut-off for participation in this research trial below 30 years of age?
"Those hoping to be included in this clinical trial must fall within the age range of 18-85. The study features 101 studies for minors and 1422 research opportunities for seniors."
Is it possible for me to become a participant in this clinical trial?
"To qualify for this clinical trial, potential participants must exhibit insulin resistance and be between 18 to 85 years old. The total number of admitted patients is 44 individuals."
How many participants are enrolled in this research endeavor?
"Affirmative. According to the information on clinicaltrials.gov, this medical research was established on December 1st 2021 and is presently seeking 44 participants from a single site. The trial has been recently updated as of June 30th 2022."
Does the administration of Pioglitazone 30 mg pose any substantial health risks?
"Our group at Power analyzed the safety of Pioglitazone 30 mg and determined that this Phase 2 trial, which has some evidence supporting its security but no proof for efficacy, deserves a rating of 2."
Could you provide a catalog of research projects utilizing Pioglitazone 30 mg?
"Presently, there are 31 clinical trials examining the efficacy of Pioglitazone 30 mg. Of those, 4 have reached Phase 3 status. These studies primarily occur in Lausanne, Vaud; however 69 other locations worldwide are running these same trials."
Share this study with friends
Copy Link
Messenger